


Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

Alderaan Biotechnology raises €18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi

Domain Therapeutics and Pr Michel Bouvier (IRIC Montreal) receive the RSRI award for bioSens-All™ project at ADRIQ-RCTi Innovation Prize gala
Advent France Biotechnology participe au tour d’amorçage de 4,2 millions d’euros d’Augustine Therapeutics

Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

Urania Therapeutics closes a €3.5M initial seed round

Nosopharm welcomes Jacques Biton and Frédéric Hammel to its supervisory board

Alaxia joins EU consortium to combat drug-resistant lung infections
